Updates in targeted therapy for melanoma

Source: eCancer, June 2018

Dr Schadendorf speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago about conference highlights in treating skin cancers.

He highlights the data from a trial of pembrolizumab plus epacadostat, which was negative, and survival data from studies of adjuvant nivolumab.

Menu